Clean-Label, Your Way Lonza Consumer Health & Nutrition creates innovative clean-label supplement solutions that address real consumer health needs while supporting wellness aspirations. Unique in our expertise, and exceptional thanks to our fully-integrated capabilities, we connect the dots by leveraging science-backed ingredients, advanced formulations, and innovative, plant-based dosage forms and...
The industry is buzzing about “clean label,” but what does it even mean? “Clean-label can mean a lot of things—to some people it means using as few ingredients as possible, to other people, it means non-GMO and natural ingredients, and to others still, it means only using ingredients that the...
Basel, Switzerland—Lonza has published its online Annual Report and its 2019 Sustainability Report, according to a press release. The 2019 edition of the Annual Report includes personal perspectives from the leadership, along with five main sections: A company overview covering strategy, talent attraction and retention, and sustainability Segments Financials Remuneration...
Basel, Switzerland—Lonza announced its full-year 2019 group results in a press release. Sales for the year grew 6.8% to $5.9 billion Swiss francs. CORE EBITDA was 27.4%. Highlights: Lonza spotlighted Pharma Biotech & Nutrition (LPBN) as a driver, with 11% sales growth despite a contraction in the nutritional hard capsules...
Basel, Switzerland—Lonza announced in a press release that Marc Funk, CEO, is leaving the company for personal reasons. Albert Baehny, Chairman of the Board of Directors, will be interim CEO until a permanent successor is found. Funk will stay until January 2020 to ensure a smooth handover. Lonza also announced...
Copenhagen, Denmark and Basel, Switzerland–Chr. Hansen Holding A/S and Lonza AG announced that they have received the necessary approvals from anti-trust regulators to establish BacThera--a 50/50 joint venture in the emerging market for live biotherapeutic products. BacThera will be headquartered in Basel, Switzerland, and is now engaging with its first...
Basel, Switzerland--Lonza announced in a press release that it has experienced continued positive momentum in its core healthcare businesses in the first six months of 2019, which has driven 6.4% sales and 7.7% CORE EBITDA growth for the group, resulting in a CORE EBITDA margin of 27.8%. Driving half-year performance: the...
Basil, Switzerland—Lonza Group announced its intention in a press release to proceed with a carve-out of its Specialty Ingredients segment (LSI). LSI will remain fully owned by Lonza, but will operate under independent management with increased control over its operations and costs. Separation has already commenced and will be completed...
Basel, Switzerland—Lonza announced the segments that produced success in their Q1 in a press release, news that coincided with the results of Lonza’s Annual General Meeting. The release states that the strength of quarter 1 performance is due to the success of the Lonza Pharma Biotech and Nutrition (LPBN) segment.
Copenhagen, Denmark, and Basel, Switzerland—Lonza, a pharma contract manufacturing company, and Chr. Hansen, a bioscience company, are teaming up for a joint venture in the development and manufacturing of live biotherapeutic products for pharma and biotech customers, according to a press release. The release says that the companies are creating...
